Lung Cancer
-
The evolution of interventional pulmonology
Interventional pulmonology has rapidly evolved into a technology-driven specialty, with advances like robotic bronchoscopy and real-time imaging enabling safer, more precise access to peripheral lung lesions. These innovations allow clinicians to combine diagnostic and therapeutic procedures in a single setting.
-
Link between viral pneumonia, lung cancer risk underlies importance of vaccination against respiratory infections
New data add weight to the case for protecting against respiratory viruses as part of lung cancer prevention.
-
Real-world data show adherence to nodal dissection standard improves detection of lymph node involvement in patients with NSCLC
Increased lymph node analysis was associated with a 2.1% absolute increase in pathologic nodal upstaging, according to recent research.
-
AI-enabled approaches poised to transform diagnosis, management of lung diseases
Experts explore how AI-based tools can be used to bridge diagnostic challenges and address unmet needs in chronic respiratory disease care.
-
AI tools like Sybil poised to improve lung cancer screening, risk prediction
The Sybil model has shown promising results in predicting lung cancer risk in diverse populations from a single CT scan, which could address gaps and disparities in current screening guidelines.
-
AI applications in pulmonary medicine: From training clinicians to transforming diagnostics and treatment
AI applications in health care are multiplying, and AI-focused research is gaining traction across specialties, including pulmonary, critical care, and sleep medicine.
-
Early data suggest air pollution may initiate lung cancer
Researcher Peiyao Wang said early results show that fine particulate matter is causing permanent DNA damage, which could have implications for lung cancer screening.
-
Imaging panel discusses pace, direction of practical AI applications
Amit Gupta, MD, MRMD, CIIP, spoke about the growing application of AI imagery in early-stage lung cancer detection.
-
Osimertinib plus chemo beat chemo alone in patients with advanced EGFR-mutated NSCLC who advanced on first-line osimertinib
Experts said the results of the COMPEL trial support continued treatment with osimertinib beyond progression in this patient population.
-
Case discussions to address complexities of mediastinal lymphadenopathy diagnosis
Sebastian Kurz, MD, PhD, FCCP, will chair a Wednesday afternoon panel session that will guide attendees through imaging findings, differential diagnoses, and clinical decision-making in mediastinal lymphadenopathy.
